logo
Plus   Neg
Share
Email

Astellas Pharma, FibroGen Announce Approval Of Evrenzo In Japan - Quick Facts

Astellas Pharma Inc. (ALPMY,ALPMY) and FibroGen, Inc. (FGEN) reported the approval of Evrenzo (generic name: roxadustat) in Japan for the treatment of anemia associated with chronic kidney disease in dialysis patients. This is the first approval for roxadustat through the Astellas and FibroGen association.

Roxadustat is also in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes.

Peony Yu, Chief Medical Officer, FibroGen, said: "With this approval in Japan, NDA approval in China, and EU MAA and US NDA preparations underway, we are another step closer to our goal of addressing the significant unmet medical need of patients living with anemia of chronic kidney disease, worldwide."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Daimler AG, the maker of Mercedes-Benz cars, said Thursday that it has agreed to pay more than $2.2 billion to settle U.S. claims over emissions from its diesel vehicles. A new class-action lawsuit filed against Facebook accuses the company's photo and video-sharing app Instagram of illegally collecting biometric data of as many as 100 million users without their consent, according to reports. The lawsuit filed in a state court in California, alleges that Instagram uses its photo-tagging technology to create a database of users' facial features. Stein Mart, Inc. has joined the ever growing list of U.S. retailers who filed for bankruptcy protection amid the ongoing coronavirus (COVID-19) pandemic. The beleaguered off-price retailer filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Middle District of Florida.
RELATED NEWS
Follow RTT